Cumberland Pharmaceuticals, Inc. (CPIX) CEO A. J. Kazimi on Q1 2021 Results - Earnings Call Transcript

Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) Q1 2021 Earnings Conference Call May 11, 2021 4:30 PM ET

Corporate Participants

Erin Gull - Corporate Relations Manager
A. J. Kazimi - Chairman and Chief Executive Officer
Marty Cearnal - President and Chief Commercial Officer
Michael Bonner - Chief Financial Officer

Conference Call Participants

Operator

Thank you for joining Cumberland Pharmaceuticals First Quarter 2021 Financial Report and Company Update. This call is being recorded at the company's request and will be archived on Cumberland's website for one week from today's date. Now I would like to introduce Erin Gull, who is responsible for Corporate Relations at Cumberland. Erin, please go ahead.

Erin Gull

Good afternoon, everyone. Today, we issued a press release containing the company's financial results and corporate update for the first quarter ended March 31, 2021. That release with related financial table is available on our website at www.cumberlandpharma.com. Please note that today's discussion may include forward-looking statements as defined in the Private Securities Reform Act of 1995. And because any such statements reflect the company's current views and expectations concerning future events, they may involve some risks and uncertainties.

Additionally, there are many factors that could affect the company's future results, including, but not limited to, natural disasters, public health epidemics, economic downturns and other events beyond our control. Those issues are described under the caption Risk Factors in our Form 10-K and any additional updates we filed with the SEC. And any forward-looking statements made during today's call are qualified by those risk factors. Also despite our best efforts, actual results could differ materially from our expectations and the information shared on this call should be considered current as of today only.

Please remember that the company does not assume any responsibility to update any forward-looking statements, whether as a result of